ArticleInternational journal of general medicine2026
Immunological and Inflammatory Characteristics of Severe Cutaneous Adverse Drug Reactions: A Retrospective Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe cutaneous adverse drug reaction (SCADR) is a life-threatening immune-mediated disorder, yet humoral immune markers and inflammatory biomarkers have not been systematically characterized across major SCADR phenotypes. This study aims to identify the immunological and inflammatory characteristics of SCADR. Methods: We retrospectively enrolled 60 SCADR patients (2015-2024) and two control cohorts (60 mild drug eruption patients and 60 age- and sex-matched healthy subjects). Baseline serum IgG, IgA, IgM, complement C3/C4, C-reactive protein (CRP), and procalcitonin (PCT) were measured prior to treatment, and between-group comparisons, correlation analyses, and subtype analyses [Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) vs DRESS] were performed. Results: SCADR patients had lower IgG (8.8±4.1g/L) and complement levels (C3 1.01±0.37g/L; C4 0.21±0.12g/L) than controls ( Conclusion: SCADR is associated with concurrent alterations in humoral immune markers and acute-phase inflammatory biomarkers. Differences in biomarker patterns between SJS/TEN and DRESS may help with early clinical phenotyping. Prospective multicenter studies are needed to validate these findings and clarify their clinical significance subsequently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.